Clinical Trial Update: Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating a combination of elotuzumab, daratumumab, iberdomide, and dexamethasone in relapsed multiple myeloma and is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• DEXAMETHASONE (Dexamethasone)
• Empliciti (elotuzumab)
• iberdomide (iberdomide)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING